AJMC®: Could you describe the current standard of care for Demodex blepharitis and how it has evolved? PERIMAN: The understanding and management of Demodex blepharitis have evolved quite a bit in ...
Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around ...
An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment. This is a video synopsis/summary of an Insights ...
Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle. Xdemvy ™ (lotilaner ophthalmic solution) is now available for the ...
Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...
John Cena opens up about his overlooked eye disease and the diagnosis that changed his approach to health.
The FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) as the first specific treatment for Demodex blepharitis. Lotilaner (formerly TP-03) is an ectoparasiticide that targets Demodex mites, ...
Please provide your email address to receive an email when new articles are posted on . Demodex blepharitis is so common that it makes up more than two thirds of all blepharitis cases. In fact, nearly ...
Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Please provide your email address to receive an email when new articles are posted on . The “Mite Party” campaign is designed to raise awareness about Demodex blepharitis. Tarsus launched the campaign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results